Literature DB >> 20808229

A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.

David L Veenstra1, Joshua A Roth, Louis P Garrison, Scott D Ramsey, Wylie Burke.   

Abstract

PURPOSE: Evaluation of genomic tests is often challenging because of the lack of direct evidence of clinical benefit compared with usual care and unclear evidence requirements. To address these issues, this study presents a risk-benefit framework for assessing the health-related utility of genomic tests.
METHODS: We incorporated approaches from a variety of established fields including decision science, outcomes research, and health technology assessment to develop the framework. Additionally, we considered genomic test stakeholder perspectives and case studies.
RESULTS: We developed a three-tiered framework: first, we use decision-analytic modeling techniques to synthesize data, project incidence of clinical events, and assess uncertainty. Second, we defined the health-related utility of genomic tests as improvement in health outcomes as measured by clinical event rates, life expectancy, and quality-adjusted life-years. Finally, we displayed results using a risk-benefit policy matrix to facilitate the interpretation and implementation of findings from these analyses.
CONCLUSION: A formal risk-benefit framework may accelerate the utilization and practice-based evidence development of genomic tests that pose low risk and offer plausible clinical benefit, while discouraging premature use of tests that provide little benefit or pose significant health risks compared with usual care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808229      PMCID: PMC3312796          DOI: 10.1097/GIM.0b013e3181eff533

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  57 in total

Review 1.  Ethical, legal, and social implications of genomic medicine.

Authors:  Ellen Wright Clayton
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

2.  Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation.

Authors: 
Journal:  Technol Eval Cent Assess Program Exec Summ       Date:  2007-06

Review 3.  Numeracy skill and the communication, comprehension, and use of risk-benefit information.

Authors:  Ellen Peters; Judith Hibbard; Paul Slovic; Nathan Dieckmann
Journal:  Health Aff (Millwood)       Date:  2007 May-Jun       Impact factor: 6.301

4.  The efficacy of diagnostic imaging.

Authors:  D G Fryback; J R Thornbury
Journal:  Med Decis Making       Date:  1991 Apr-Jun       Impact factor: 2.583

5.  Personalized medicine in the era of genomics.

Authors:  Wylie Burke; Bruce M Psaty
Journal:  JAMA       Date:  2007-10-10       Impact factor: 56.272

6.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

Authors:  Michael A Hillman; Russell A Wilke; Steven H Yale; Humberto J Vidaillet; Michael D Caldwell; Ingrid Glurich; Richard L Berg; John Schmelzer; James K Burmester
Journal:  Clin Med Res       Date:  2005-08

7.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

8.  Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

9.  Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

Authors: 
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

Review 10.  Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin.

Authors:  Kirsten Neudoerffer Kangelaris; Stephen Bent; Robert L Nussbaum; David A Garcia; Jeffrey A Tice
Journal:  J Gen Intern Med       Date:  2009-03-21       Impact factor: 5.128

View more
  40 in total

1.  Implications of Internet availability of genomic information for public health practice.

Authors:  B W Hesse; N K Arora; M J Khoury
Journal:  Public Health Genomics       Date:  2012-04-04       Impact factor: 2.000

2.  Pharmacogenetics in clinical practice: how far have we come and where are we going?

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

Review 3.  Personal utility in genomic testing: a systematic literature review.

Authors:  Jennefer N Kohler; Erin Turbitt; Barbara B Biesecker
Journal:  Eur J Hum Genet       Date:  2017-03-15       Impact factor: 4.246

4.  Defining personal utility in genomics: A Delphi study.

Authors:  J N Kohler; E Turbitt; K L Lewis; B S Wilfond; L Jamal; H L Peay; L G Biesecker; B B Biesecker
Journal:  Clin Genet       Date:  2017-04-19       Impact factor: 4.438

5.  Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.

Authors:  Susan R Snyder; Jing Hao; Larisa H Cavallari; Zhi Geng; Amanda Elsey; Julie A Johnson; Zahurin Mohamed; Nathorn Chaiyakunapruk; Huey Yi Chong; Maznah Dahlui; Fatiha H Shabaruddin; George P Patrinos; Christina Mitropoulou; Marc S Williams
Journal:  Public Health Genomics       Date:  2019-06-12       Impact factor: 2.000

Review 6.  Systems biology approaches to adverse drug effects: the example of cardio-oncology.

Authors:  Sherry-Ann Brown; Nicole Sandhu; Joerg Herrmann
Journal:  Nat Rev Clin Oncol       Date:  2015-10-13       Impact factor: 66.675

7.  PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Authors:  James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-11       Impact factor: 3.908

8.  Easing the global burden of diarrhoeal disease: can synthetic biology help?

Authors:  Prerna Vohra; Garry W Blakely
Journal:  Syst Synth Biol       Date:  2013-07-20

9.  Genetics specialists' perspectives on disclosure of genomic incidental findings in the clinical setting.

Authors:  Nancy R Downing; Janet K Williams; Sandra Daack-Hirsch; Martha Driessnack; Christian M Simon
Journal:  Patient Educ Couns       Date:  2012-10-12

10.  Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.

Authors:  Jennifer L Hall; John J Ryan; Bruce E Bray; Candice Brown; David Lanfear; L Kristin Newby; Mary V Relling; Neil J Risch; Dan M Roden; Stanley Y Shaw; James E Tcheng; Jessica Tenenbaum; Thomas N Wang; William S Weintraub
Journal:  Circ Cardiovasc Genet       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.